-- The London Proteomics Discussion Group --
Proteomics seminar series for the South East

24th July 2020
Proteomics seminar series for the South East
Methods Challenge
---Registration is free---

About the LPDG

We are a free, local proteomics seminar series in the South East,
with a focus towards networking, discussion and supporting early career researchers.

The LPDG...

was founded to bring together the large community of proteomics scientists all working in and around London. We aim to provide a space for discussion, with a focus on methods and early career researchers (two fundamental building blocks of good research!), on all topics related to proteomics. The meetings comprise of research talks framed by a proteomics methods challenge, lunch, refreshments and pizza - they are free to attend thanks to sponsorship.

Meeting Dates:

Next Meeting


These seminars would not be possible without our amazing sponsors.
If you are interested in sponsoring an LPDG seminar,
please get in touch at sponsor@londonproteomics.co.uk

Webinar Programme

SARS-CoV-2: What Role Can Proteomics Play?

for 24th July 2020 14:00 BST
Last updated 10th July 2020

Dr Jeroen Demmers

Targeted Proteomics for the Detection of SARS-CoV-2 Proteins

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). The rapid, sensitive and specific diagnosis of SARS-CoV-2 by fast and unambiguous testing is widely recognized to be critical in responding the current outbreak. Since the current testing capacity by conventional PCR based methods is insufficient because of shortages of supplies such as RNA extraction kits and PCR reagents, alternative and/or complementary testing assays should be developed. Here, we exploit the potential of targeted mass spectrometry based proteomic technologies to solve the current issue of insufficient SARS-CoV-2 diagnostic testing capacity. We have assessed the limit of detection by parallel reaction monitoring (PRM) on an Orbitrap Eclipse mass spectrometer for target tryptic peptides of several SARS-CoV-2 proteins from a sample of virus infected Vero cells. For Nucleocapsid protein the limit of detection was found to be in the mid-attomole range (0.9 × 10−12 g), which would theoretically correspond to approximately 10,000 SARS-CoV-2 particles, under the assumption that all viral proteins are assembled in macromolecular virus particles. Whether or not this sensitivity is sufficient to play a role in SARS-CoV-2 detection in patient material such as swabs or body fluids largely depends on the amount of viral proteins present in such samples and is subject of further research. If yes, mass spectrometry based methods could serve as a complementary protein based diagnostic tool and further steps should be focused on sample preparation protocols and on improvements in sample throughput.


Prof Andreas Pichlmair

Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV

The sudden global emergence of SARS-CoV-2 urgently requires an in-depth understanding of molecular functions of viral proteins and their interactions with the host proteome. Several omics studies have extended our knowledge of COVID-19 pathophysiology, including some focused on proteomic aspects1–3. To understand how SARS-CoV-2 and related coronaviruses manipulate the host we here characterized interactome, proteome and signaling processes in a systems-wide manner. This identified connections between the corresponding cellular events, revealed functional effects of the individual viral proteins and put these findings into the context of host signaling pathways. We investigated the closely related SARS-CoV-2 and SARS-CoV viruses as well as the influence of SARS-CoV-2 on transcriptome, proteome, ubiquitinome and phosphoproteome of a lung-derived human cell line. Projecting these data onto the global network of cellular interactions revealed relationships between the perturbations taking place upon SARS-CoV-2 infection at different layers and identified unique and common molecular mechanisms of SARS coronaviruses. The results highlight the functionality of individual proteins as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs. We exemplify this by identification of kinase inhibitors as well as MMPase inhibitors with significant antiviral effects against SARS-CoV-2.


Event Speakers

Would you like to present at an LPDG meeting? Email: speaker@londonproteomics.co.uk
Research presentations from:

Dr Jeroen Demmers
Dr Jeroen Demmers
Dr Jeroen Demmers Erasmus University,

Dr Demmers is director of the proteoimcs facility at the Erasmus University Medical Center, having completed his PhD in Heck and Killian labs at Utrech University and a postdoc in the Chait lab at The Rockerfeller University, New York. His research interests in mass spectrometry and proteomics extend into quantitation, targetted proteomes, PTM analysis, transcription/gene regulation in health and disease and chromatin biology.

Prof Andreas Pichlmair
Prof Andreas Pichlmair
Prof Andreas Pichlmair School of Medicine,
Technical University of Munich

Professor Pichlmair (b. 1978) researches the interaction between viral pathogens and their host organisms. Professor Pichlmair primarily uses mass spectrometry and similar “large scale” techniques in order to conduct system analyses. The hypotheses drawn from such analyses serve to identify signaling cascades and mechanisms involved in the antiviral immune response. In 2008 he obtained a PhD from the London Research Institute, Cancer Research UK, where he was supervised by Professor Caetano Reis e Sousa. From 2008 to 2011, he worked as a post-doc at the Center for Molecular Medicine, Austria Academy of Sciences under Professor Giulio Superti-Furga. He set up his own laboratory at the Max Planck Institute of Biochemistry, Munich, as part of the Max Planck Free Floater Program (2011-2017). Professor Pichlmair took up a professorship at TUM in July 2017.




Here is a list of answers to frequently asked questions for speakers, delegates and sponsors

If you still have unanswered questions after reading this page, wish to present a talk, suggest a venue or sponsor a meeting, please contact us.

Organising Committee

The organising committee is made up of early and "not-so-early" career scientists
from academia and industry.
If you are interested in joining the committee, please get in touch.

Dr Harvey Johnston
Dr Harvey Johnston Chairperson, Founder

After my PhD in blood plasma cancer proteomics I moved to the Cancer Proteomics Group at UCL. I founded the LPDG as a focus group for the SE. I am currently at the Babraham Institute investigating protein degradation pathways using proteomics.

Dr Harry Whitwell
Dr Harry Whitwell Communications Officer

I am a post doc at ICL, developing mass spectrometry and data analysis methodology for the study of protein PTMs, in particular methylation. My research is multidisciplinary, using chemistry, bioinformatics and biology. For more info, click here.

Dr Lukas Krasny
Dr Lukas Krasny Secretary

I am a post-doc at the ICR in Paul Huang’s group. My research interest is in extracellular matrix remodelling during cancer progression. From an analytical point of view, I am interested in protein quantification by DIA mass spectrometry.

Dr Roberto Buccafusca
Dr Roberto Buccafusca Treasurer

I manage an MS lab at QMUL. I graduated from Drexel University (USA) in Biomedical Science, completing my PhD work at Harvard University. After a long stint in the private sector, I re-joined academia here in the UK researching lipidomics and proteomics.

Danai Kati
Danai Kati
Danai Kati Committee Member

Danai studied biology and biomedical sciences in Greece. She has worked in numerous labs in England, Singapore, the Netherlands and Greece. Now she is focusing on her PhD at UCL in Primary Biliary Cholangitis analyzing human samples using Mass spectrometry.

Suniya Khatun
Suniya Khatun Committee member

I am a PhD student at UCL on the CellX project in the Thalassinos Lab studying competition in cellular populations using mass spectrometry-based proteomics.

Dr Daniel Conole
Dr Daniel Conole Committee member

Daniel is a post-doc in the lab of Prof. Ed Tate at Imperial College London. His research interests lie in the use of chemical proteomics for better understanding of drug targets, protein function, and post-translational modification dynamics.

Tom Ruane
Tom Ruane Committee member

Tom works for SCIEX in the London region helping customers with MS and 'OMICS applications. He gained an interest in MS from working with Prof Roy Goodacre, Manchester Institute of Biotech. applying -omics and chemometric approaches for rapid food authenticity determination.

Emily Vitterso
Emily Vitterso Committee member

I am a PhD student in the Institute for Women's Health, UCL in the lab of Dr John Timms working on cancer proteomics.

Joanna Kirkpatrick
Dr Joanna Kirkpatrick
Dr Joanna Kirkpatrick Committee member

Joanna Kirkpatrick
Crick Insitute

London and the South East
United Kindgom

Please email with any questions.
Particularly welcome are venue suggestions,
speaker suggestions or if you are thinking of sponsoring a meeting.

This seminar series is run by volunteers from academia and industry. We will try to reply to your email as quickly as possible, but please allow at least 5 days.